Liposomal Amphotericin B, and Not Amphotericin B Deoxycholate, Improves Survival of Diabetic Mice Infected with Rhizopus oryzae-Reference-Cited by-同舟云学术

Liposomal Amphotericin B, and Not Amphotericin B Deoxycholate, Improves Survival of Diabetic Mice Infected with Rhizopus oryzae

Published:2003-10 Issue:10 Volume:47 Page:3343-3344
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ibrahim Ashraf S.¹²,Avanessian Valentina¹,Spellberg Brad¹,Edwards John E.¹²

Affiliation:

1. Harbor-UCLA Research and Education Institute, Torrance, California 90502

2. UCLA School of Medicine, Los Angeles, California 90024

Abstract

ABSTRACT The efficacies of liposomal amphotericin B (LAmB) and amphotericin B deoxycholate (AmB) were compared in a diabetic murine model of hematogenously disseminated Rhizopus oryzae infection. At 7.5 mg/kg of body weight twice a day (b.i.d.), LAmB significantly improved overall survival compared to the rates of survival in both untreated control mice ( P = 0.001) and mice treated with 0.5 mg of AmB per kg b.i.d. ( P = 0.047). These data indicate that high-dose LAmB is more effective than AmB in treating murine disseminated zygomycosis.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.47.10.3343-3344.2003

Reference14 articles.

1. Adler-Moore, J., and R. T. Proffitt. 2002. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J. Antimicrob. Chemother.49(Suppl. 1):21-30.

2. Boelaert, J. R. 1994. Mucormycosis (zygomycosis): is there news for the clinician? J. Infect.28(Suppl. I):1-6.

3. Cagatay, A. A., S. S. Oncu, S. S. Calangu, T. T. Yildirmak, H. H. Ozsut, and H. H. Eraksoy. 2001. Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: a case report. BMC Infect. Dis.1:22. [Online.] http://www.biomedcentral.com/1471-2334/1/22 .

4. Dupont, B. 2002. Overview of the lipid formulations of amphotericin B. J. Antimicrob. Chemother.49(Suppl. 1):31-36.

5. Edwards J. E. Jr. 1989. Zygomycosis p. 1192-1199. In P. D. Hoeprich and M. C. Jordan (ed.) Infectious disease 4th ed. J. B. Lippincott Co. Philadelphia Pa.

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antifungal activity of alexidine dihydrochloride in a novel diabetic mouse model of dermatophytosis;Frontiers in Cellular and Infection Microbiology;2022-09-02

2. Pulmonary mucormycosis: An anaesthesiologist's perspective;Hamdan Medical Journal;2022

3. Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than Aspergillus in the haematology/oncology setting, 2021;Internal Medicine Journal;2021-11

4. Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis;Journal of Antimicrobial Chemotherapy;2021-07-15

5. Invasive fungal diseases in renal transplantation - Case series;Indian Journal of Transplantation;2021